Not finding it? Sign in to also search OpenAlex live.
-
Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial2022 The American Journal of Medicine article Medicine Atrial Fibrillation Management and Outcomes Open access
Renato D. Lópes, Patrícia O. Guimarães, Gregory G. Schwartz, Deepak L. Bhatt, Vera Bittner, Andrzej Budaj, +12 more
6citations -
Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
José Tuñón, Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, Shaun G. Goodman, +11 more
76citations -
Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial2020 European Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Rafael Díaz, Qian H Li, Deepak L. Bhatt, Vera Bittner, Marie T. Baccara‐Dinet, Shaun G. Goodman, +13 more
58citations -
Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
Gregory G. Schwartz, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, Maja Bujas‐Bobanovic, Rafael Díaz, +11 more
47citations -
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial2020 European Heart Journal article Medicine Lipoproteins and Cardiovascular Health Open access cited by 2 patents
Michael J. Szarek, Vera Bittner, Philip E. Aylward, Marie T. Baccara‐Dinet, Deepak L. Bhatt, Rafael Díaz, +16 more
221citations -
Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial2023 Journal of the American Heart Association article Medicine Lipoproteins and Cardiovascular Health Open access
Shaun G. Goodman, Philippe Gabríel Steg, Yann Poulouin, Deepak L. Bhatt, Vera Bittner, Rafael Díaz, +8 more
43citations -
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial2022 The Lancet Diabetes & Endocrinology article Medicine Lipoproteins and Cardiovascular Health Open access
Philippe Gabríel Steg, Deepak L. Bhatt, Vera Bittner, Michael J. Szarek
38citations -
Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial2026 European Journal of Preventive Cardiology article Medicine Lipoproteins and Cardiovascular Health
Philippe Gabríel Steg, Michael J. Szarek, Vera Bittner, Deepak L. Bhatt, Rafael Díaz, Shaun G. Goodman, +8 more
0citations -
Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES2022 Canadian Journal of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Chern‐En Chiang, Gregory G. Schwartz, Yedid Elbez, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, +11 more
14citations -
Alirocumab and cardiovascular outcomes according to sex and lipoprotein(a) after acute coronary syndrome: a report from the ODYSSEY OUTCOMES study2024 Journal of clinical lipidology article Medicine Lipoproteins and Cardiovascular Health Open access
Vera Bittner, Gregory G. Schwartz, Deepak L. Bhatt, Terrance Siang Jin Chua, H. Asita De Silva, Rafael Díaz, +10 more
26citations -
Abstract 13567: Comparison of Change in Lipoprotein(a) Mass and Molar Concentrations by Alirocumab and Risk of Subsequent Cardiovascular Events in ODYSSEY OUTCOMES
Michael J. Szarek, Esther Reijnders, Philippe Gabríel Steg, J. Wouter Jukema, Markus Schwertfeger, Deepak L. Bhatt, +10 more
0citations -
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome2024 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Doron Zahger, Gregory G. Schwartz, Weiming Du, Michael J. Szarek, Deepak L. Bhatt, Vera Bittner, +15 more
15citations -
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes2020 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Deepak L. Bhatt, Andrew H. Briggs, Shelby D. Reed, Lieven Annemans, Michael J. Szarek, Vera Bittner, +23 more
64citations -
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol2021 Journal of the American College of Cardiology article Medicine Lipoproteins and Cardiovascular Health Open access
Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo, Garen Z. Manvelian, Robert C. Pordy, Michel Scemama, +61 more
147citations